geen healthy volunteers none
Conditions
Interventions
Single oral dose of atomoxetine (60 mg), and placebo, double-blind.
Sponsors
Vrije Universiteit
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: personality questionnaire filled out 18-30 years old informed consent normal intelligence
Exclusion criteria
Exclusion criteria: diagnosis of psychopathology disease affecting brain function, such as epilepsy smoking or self-reported drug abuse use of medication, in particular antidepressants pregnancy history of heart disease hypertension
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Outcome parameters are: behavioral measures of the von Restorff effect, the novelty preference and the learning rate in a reinforcement-learning framework; and non-invasive electrophysiological measures in the form of event-related potentials. Our hypothesis is that Atomoxetine will lead to strengthened novelty responses, namely: higher amplitudes in the P3a and N2 components, a stronger von Restorff effect when evaluated with a bimodal (visual and auditory) task, higher novelty preference when tested with a visual paired comparison task, and higher learning rates. | — |
Secondary
| Measure | Time frame |
|---|---|
| Novelty-related personality traits using the TPQ questionnaire and the baseline memory span of the participants, and trait anxiety as estimated with the STAI personality test. Polymorphisms of the following seven genes affecting the noradrenergic system: NET, DBH and COMT, and the alpha-1, alpha-2, beta-1, beta-2 adrenergic receptor genes. | — |
Countries
Netherlands
Outcome results
None listed